# C_2011005EN.01001301.xml

| 8.1.2011 | EN | Official Journal of the European Union | C 5/13 |
| --- | --- | --- | --- |

8.1.2011

EN

Official Journal of the European Union

C 5/13

---

Prior notification of a concentration

(Case COMP/M.6033 — Johnson & Johnson/Crucell)

Candidate case for simplified procedure

(Text with EEA relevance)

2011/C 5/11

| 1. | On 20 December 2010, the Commission received a notification of a proposed concentration pursuant to Article 4 and following a referral pursuant to Article 4(5) of Council Regulation (EC) No 139/2004 (1) by which Johnson & Johnson (‘JNJ’, USA) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of over Crucell N.V. (‘Crucell’, the Netherlands) by way of public bid announced on 6 October 2010. |
| --- | --- |

1.

On 20 December 2010, the Commission received a notification of a proposed concentration pursuant to Article 4 and following a referral pursuant to Article 4(5) of Council Regulation (EC) No 139/2004 (1) by which Johnson & Johnson (‘JNJ’, USA) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of over Crucell N.V. (‘Crucell’, the Netherlands) by way of public bid announced on 6 October 2010.

1

| 2. | The business activities of the undertakings concerned are:






  — | JNJ: consumer health and care products, including beauty, oral care, baby, over-the-counter medicines, nutritional, women's health, wellness and prevention products; medical devices and diagnostics; pharmaceutical products, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

JNJ: consumer health and care products, including beauty, oral care, baby, over-the-counter medicines, nutritional, women's health, wellness and prevention products; medical devices and diagnostics; pharmaceutical products,

| — | Crucell: research, development, production and sale of biologic medicinal products (i.e. vaccines, proteins and antibodies) for the prevention or treatment of infectious diseases. |
| --- | --- |

—

Crucell: research, development, production and sale of biologic medicinal products (i.e. vaccines, proteins and antibodies) for the prevention or treatment of infectious diseases.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the EC Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the EC Merger Regulation (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the EC Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the EC Merger Regulation (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

2

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.6033 — Johnson & Johnson/Crucell, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.6033 — Johnson & Johnson/Crucell, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘EC Merger Regulation’).

1

(2)  OJ C 56, 5.3.2005, p. 32 (‘Notice on a simplified procedure’).

2

---